HSV-2 serologic testing in an HMO population: uptake and psychosocial sequelae

Sex Transm Dis. 2007 Sep;34(9):718-25. doi: 10.1097/01.olq.0000261455.60955.59.

Abstract

Objectives: To prospectively measure the uptake of Herpes simplex virus Type 2 (HSV-2) testing and psychosocial response to a new serologic diagnosis of HSV-2 in a health maintenance organization (HMO) population.

Study design: Randomly selected urban HMO enrollees were invited to be tested for HSV-2 antibody at a research clinic. Participants had blood drawn and completed demographic and psychosocial questionnaires.

Results: Of 3111 eligible enrollees contacted, 344 (11%) were tested. Eighty-seven (26%) tested HSV-2 seropositive, and 44 (51%) of these did not report a prior genital herpes diagnosis. Distress, measured by the total mood disturbance, was 6.5 points higher on average following a new genital herpes diagnosis relative to baseline (actual range = 109 points, P = 0.003) but not statistically different from HSV-2 negative or previously diagnosed participants.

Conclusions: HMO enrollees unexpectedly testing HSV-2 positive showed short-term psychosocial distress that resolved during 6-month follow-up. Findings suggest that concerns about psychosocial burden should not deter voluntary serologic HSV-2 testing in primary care settings.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antibodies, Viral / blood*
  • Counseling
  • Female
  • Health Maintenance Organizations*
  • Herpes Genitalis / diagnosis*
  • Herpes Genitalis / epidemiology
  • Herpes Genitalis / psychology*
  • Herpesvirus 2, Human / immunology*
  • Humans
  • Male
  • Middle Aged
  • Patient Acceptance of Health Care*
  • Prospective Studies
  • Serologic Tests
  • Washington / epidemiology

Substances

  • Antibodies, Viral